Contemporary tools for the diagnosis and management of invasive mycoses

被引:95
作者
Alexander, Barbara D.
Pfaller, Michael A.
机构
[1] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Dept Med, Durham, NC 27710 USA
[2] Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA
关键词
D O I
10.1086/504491
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Invasive fungal infections have become a major cause of morbidity and mortality over the past 3 decades. Organ transplantation, the use of aggressive chemotherapy, and the availability and widespread use of immunosuppressive treatments for many medical ailments have resulted in large populations of patients who are at risk for fungal disease. Early diagnosis and prompt therapy are instrumental to successful treatment of these infections, but conventional methods for diagnosis of fungal disease are slow and lack sensitivity. Important advances in diagnosing invasive mycoses, particularly in laboratory-based testing, have been realized over the years. Antigen-based assays, new laboratory methods for identification of fungi, and reference guidelines for susceptibility testing have been developed and validated for use in clinical laboratories. We review these technological advances and our understanding of their clinical application and impact.
引用
收藏
页码:S15 / S27
页数:13
相关论文
共 105 条
  • [1] Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies
    Adam, O
    Aupérin, A
    Wilquin, F
    Bourhis, JH
    Gachot, B
    Chachaty, E
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (06) : 917 - 920
  • [2] Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures
    Alexander, BD
    Ashley, ED
    Reller, LB
    Reed, SD
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 54 (04) : 277 - 282
  • [3] [Anonymous], 2003, Manual of clinical microbiology
  • [4] Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia
    Baddley, JW
    Patel, M
    Jones, M
    Cloud, G
    Smith, AC
    Moser, SA
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 50 (02) : 119 - 124
  • [5] Quality control limits for fluconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue
    Barry, A
    Bille, J
    Brown, S
    Ellis, D
    Meis, J
    Pfaller, M
    Rennie, R
    Rinaldi, M
    Rogers, T
    Traczewski, M
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (07) : 3410 - 3412
  • [6] Quality control limits for broth microdilution susceptibility tests of ten antifungal agents
    Barry, AL
    Pfaller, MA
    Brown, SD
    Espinel-Ingroff, A
    Ghannoum, MA
    Knapp, C
    Rennie, RP
    Rex, JH
    Rinaldi, MG
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) : 3457 - 3459
  • [7] Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus
    Bartizal, C
    Odds, FC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2100 - 2107
  • [8] Direct identification and recognition of yeast species from clinical material by using albicans ID and CHROMagar Candida plates
    Baumgartner, C
    Freydiere, AM
    Gille, Y
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (02) : 454 - 456
  • [9] Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis
    Becker, MJ
    Lugtenburg, EJ
    Cornelissen, JJ
    van der Schee, C
    Hoogsteden, HC
    de Marie, S
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (03) : 448 - 457
  • [10] *BIORAD LAB, 2003, PLAT ASP EIA PACK IN